IL-2 Family Cytokines and Receptors-- Mechanisms of Regulation & Action
IL-2 家族细胞因子和受体——调节机制
基本信息
- 批准号:8746596
- 负责人:
- 金额:$ 130.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Adoptive ImmunotherapyAdoptive TransferAdultAllergicApoptosisApoptosis Regulation GeneAreaAutoimmune ProcessB-LymphocytesBindingBiologicalBiological ProcessBoxingCD27 AntigensCD4 Positive T LymphocytesCD8B1 geneCell Differentiation processCell physiologyCellsChIP-seqClinicalColitisCollaborationsComplexCoupledCytokine ReceptorsCytokine SignalingDNA Sequence AnalysisDefectDendritic CellsDevelopmentDiseaseElementsEventExhibitsFamilyGalactosylceramidesGene ExpressionGene TargetingGenesGenetic TranscriptionGranulocyte-Macrophage Colony-Stimulating FactorHelminthsHelper-Inducer T-LymphocyteHost DefenseHumanHuman T-lymphotropic virus 1IRF4 geneImmune responseImmune systemIndiumInflammatoryInflammatory Bowel DiseasesInjection of therapeutic agentInterferonsInterleukin 2 ReceptorInterleukin 2 Receptor GammaInterleukin-10Interleukin-15Interleukin-17Interleukin-2Interleukin-4Interleukin-7Interleukin-9Leucine ZippersMAPK Signaling Pathway PathwayMalignant - descriptorMalignant NeoplasmsMediatingMolecular ProfilingMusMutateNatural ImmunityNormal CellPRDM1 genePhenotypePopulationProcessProductionPropertyProteinsProto-Oncogene Proteins c-junPsoriasisRegulationReportingResponse ElementsRoleSTAT proteinSTAT3 geneSTAT5A geneSTAT5B geneSignal TransductionSpinal Cord DiseasesSystemT-Cell ActivationT-Cell LeukemiaT-Cell LymphomaT-Cell ReceptorT-LymphocyteT-bet proteinTh2 CellsTimeTranscription Factor AP-1Transgenic MiceTransgenic ModelTropical Spastic ParaparesisVariantVirusX-Linked Severe Combined Immunodeficiencybasecancer therapychromatin immunoprecipitationcytokinegenome-widehuman diseasein vivoinsightinterleukin-12 receptorkiller T cellneoplasticneoplastic cellnovelpathogenpreventprotein expressionreceptorresponsethree dimensional structuretranscription factortumor
项目摘要
The interleukin-2 receptor and related cytokine/cytokine receptor systems are being studied to understand critical components of the T cell immune response in normal and neoplastic cells. Following T-cell activation, IL-2 and IL-2 receptors are induced; the magnitude and duration of the T-cell immune response is controlled by the amount of IL-2 produced, the levels of receptors expressed, and the time course of these events. Expression of IL-2Ra is interestingly high in cells infected with HTLV-I, the cause of adult T cell leukemia (ATL) and tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). Three chains of the IL-2 receptor exist, IL-2Ra, IL-2Rb, and gc, with IL-2Ra and IL-2Rb being significantly regulated at the level of transcription. gc is a shared chain also used by the receptors for IL-4, IL-7, IL-9, IL-15, and IL-21, and is the protein that is mutated in XSCID. We have focused primarily on the types of signals induced by some of these cytokines, particularly the activation of STAT proteins (signal transducers and activators of transcription), and the mechanism by which they regulate cytokine/STAT target genes. Given our prior observations that STAT5A or STAT5B transgenic mice develop tumors, which was consistent with STAT5 being implicated in malignant transformation and elevated in a range of human tumors, this is an important area for both normal and pathological states. Moreover, humans and mice with defective STAT protein expression have a range of immunological defects. In the past year, in a collaboration, we reported that enhanced T cell lymphoma in NOD-Stat5b transgenic mice is caused by hyperactivation of STAT5B in CD8+ T cells.
T helper cell differentiation is critical for normal immune responses, with Th1 differentiation being important for host defense to viruses and other intracelllular pathogens, Th2 differentiation being vital in allergic disorders and related to helminths, and Th17 differentiation being vital in a range of inflammatory disorders, including psoriasis and inflammatory bowel disease. We previously showed that IL-2 is important for Th2 differentiation and reported that IL-2 regulates expression of the IL-4 receptor in a STAT5-dependent manner and critically controls priming of cells for Th2 differentiation. Moreover, using genome-wide Ilumina-based ChIP-Seq (chromatin immunoprecipitation coupled to DNA sequencing) analysis, we previously discovered broad regulation of Th2 differentiation via STAT5A and STAT5B, substantially extending earlier studies focused on STAT5A. Moreover, we had discovered that IL-2-mediated IL-4Ra induction was critical in priming cells for Th2 differentiation. In the prior year, we substantially extended these findings by showing that IL-2 via STAT5 induces expression of IL-12Rb1 and IL-12Rb2 and that the induction of IL-12Rb2 is critical for Th1 differentiation and we defined the mechanism of regulation of IL-12Rb2. Additionally, we showed that IL-2 via STAT5 also regulates the T box protein, T-bet. Interestingly, in contrast to the induction of IL-12R proteins, IL-2 inhibits expression of IL-6Ra and gp130, helping to explain the inhibition of Th17 differentiation. Consistent with the ability of Tbx21 to inhibit Th17 differentiation, expression of Tbx21 in Th17 cells resulted in increased IFNg but decreased expression of IL-17A. These results indicated a very broad effect of IL-2 via STAT5 on T helper cell differentation.
In the current review year, we have continued to study the role of IL-2 in Th differentiation, including related to Th9 differentiation. During the past year, we also continued our collaboration with Dr. K. Christopher Garcia at Stanford, studying the actions of wild type IL-2 versus novel IL-2 variants, a project with potential clinical ramifications. These studies in part use the pmel-1 T cell receptor transgenic model of adoptive immunotherapy for cancer in collaboration with Dr. Nicholas Restifo, NCI. We have also collaborated with Dr. Garcia on a project in which the three dimensional structure of IL-2 complexed to its receptor was compared to that of IL-15 bound to its receptor. These studies, reported in the past year, have provided key mechanistic and structural insights into the functional differences between IL-2 and IL-15, which are highly related and share IL-2Rbeta and gc as receptor components but nevertheless possess distinctive biological functions. Although IL-2 primarily signals via cis-signaling and IL-15 via trans-signaling, these cytokines have essentially identical activation of STAT, PI3K/Akt, and Ras/MAPK signaling pathways. Moreover, gene expression profiles are very similar, although not identical. Thus, these cytokines have almost indistinguishable signaling properties despite different biological responses. This study has substantially elucidated structural and mechanistic aspects of IL-2 and IL-15 signaling.
Previously, we demonstrated that IL-21 regulated expression of the Prdm1 gene that encodes BLIMP1 via a response element that depends on STAT3 and IRF4. This led to our reporting in the past year that in contrast to its known ability to cooperate with PU.1 in B cells to act via Ets-IRF composite elements (EICEs), IRF4 cooperates with BATF/JUN family proteins to act via AP1-IRF composite elements (AICEs) in T cells, as well as in B cells. We demonstrated critical cooperative regulation of important genes via these AICEs and demonstrated cooperative binding of IRF4, BATF, and JUN family proteins, with markedly diminished IRF4 binding in Batf-deficient cells and markedly diminished BATF binding in Irf4-deficient cells. We demonstrated critical regulation of key genes, including for example those encoding IL-10 and IL-17 via AICEs. In collaborative studies with Ken Murphy, we also reported that there were important compensatory roles for BATF factors in dendritic cell development mediated by BATF-IRF interactions involving the leucine zipper domain of BATF.
We also reported key actions of cross-talk between IL-21/STAT3 and GM-CSF/STAT5. IL-21 has broad actions on T- and B-cells, but its actions in innate immunity are poorly understood. We reported that IL-21 induced apoptosis of conventional dendritic cells (cDCs) via STAT3 and Bim, and this was inhibited by granulocyte-macrophage colony-stimulating factor (GM-CSF). ChIP-Seq analysis revealed genome-wide binding competition between GM-CSF-induced STAT5 and IL-21-induced STAT3. Expression of IL-21 in vivo decreased cDC numbers, and this was prevented by GM-CSF. Moreover, repetitive α-galactosylceramide injection of mice induced IL-21 but decreased GM-CSF production by natural killer T (NKT) cells, correlating with decreased cDC numbers. Furthermore, adoptive-transfer of wild-type CD4+ T cells caused more severe colitis with increased DCs and interferon (IFN)-γ-producing CD4+ T cells in Il21r-/-Rag2-/- mice (which lack T cells and have IL-21-unresponsive DCs) than in Rag2-/- mice. Thus, IL-21 and GM-CSF exhibit cross-regulatory actions on gene regulation and apoptosis, regulating cDC numbers and thereby the magnitude of the immune response.
Overall, the above findings enhance our understanding of mechanisms by which the gc family cytokines regulate gene expression and biologically important processes. In addition, these findings have implications related to the treatment of cancer, autoimmune, and other diseases.
正在研究白细胞介素-2受体和相关的细胞因子/细胞因子受体系统,以了解正常和肿瘤细胞中T细胞免疫反应的关键成分。 T细胞激活后,诱导IL-2和IL-2受体。 T细胞免疫反应的大小和持续时间受到产生的IL-2的量,表达的受体水平以及这些事件的时间过程的控制。在感染HTLV-I的细胞中,IL-2RA的表达很高,HTLV-I是成年T细胞白血病(ATL)和热带痉挛性模拟的原因/HTLV-I相关性脊髓病(TSP/HAM)。 IL-2受体的三个链,IL-2RA,IL-2RB和GC存在,IL-2RA和IL-2RB在转录水平下受到显着调节。 GC是一个共享链也由受体用于IL-4,IL-7,IL-9,IL-15和IL-21,并且是在XSCID中突变的蛋白质。我们主要集中于这些细胞因子中的某些信号的类型,尤其是STAT蛋白的激活(信号转录器和转录的激活因子),以及它们调节细胞因子/STAT靶基因的机制。鉴于我们先前的观察到STAT5A或Stat5b转基因小鼠会发展肿瘤,这与STAT5与恶性转化有关,并且在一系列人类肿瘤中升高,这是正常状态和病理状态的重要区域。此外,具有缺陷统计蛋白表达的人类和小鼠具有一系列免疫缺陷。在过去的一年中,我们报告说,NOD-STAT5B转基因小鼠的T细胞淋巴瘤增强是由CD8+ T细胞中Stat5b的过度激活引起的。
T辅助细胞分化对于正常的免疫反应至关重要,Th1的分化对于宿主防御对病毒和其他细胞内病原体至关重要,Th2分化在过敏性疾病中至关重要,并且与舵机有关,TH17分化对于包括牛皮癣和炎症性弓箭疾病在内的炎症性疾病中至关重要。我们先前表明,IL-2对于TH2分化很重要,并报告IL-2以STAT5依赖性方式调节IL-4受体的表达,并严格控制细胞的TH2分化启动。此外,使用基于全基因组iLumina的芯片seq(染色质免疫沉淀与DNA测序结合)分析,我们先前通过STAT5A和STAT5B发现了对TH2分化的广泛调节,从而大大扩展了较早的研究,该研究集中在STAT5A上。此外,我们发现IL-2介导的IL-4RA诱导对于Th2分化的启动细胞至关重要。在上一年中,我们通过表明IL-2通过STAT5诱导IL-12RB1和IL-12RB2的表达来大大扩展了这些发现,并且IL-12RB2的诱导对于TH1的分化至关重要,我们定义了IL-12RB2调节的机制。此外,我们表明IL-2通过STAT5还调节T盒蛋白T-bet。有趣的是,与诱导IL-12R蛋白的诱导相反,IL-2抑制了IL-6RA和GP130的表达,有助于解释Th17分化的抑制作用。与TBX21抑制Th17分化的能力一致,Th17细胞中TBX21的表达导致IFNG增加,但IL-17A的表达降低。这些结果表明,IL-2通过STAT5对T辅助细胞分化产生了非常广泛的影响。
在当前的审查年中,我们继续研究IL-2在TH分化中的作用,包括与TH9分化有关。在过去的一年中,我们还继续与斯坦福大学K. Christopher Garcia博士的合作,研究了野生IL-2与新颖的IL-2变体的行为,这是一个潜在的临床后果的项目。这些研究部分使用了与NCI的Nicholas Restifo博士合作的PMEL-1 T细胞受体转基因模型的癌症。我们还与Garcia博士合作进行了一个项目,在该项目中,将IL-2的三维结构与其受体结合的IL-15进行了比较。这些研究在过去一年中报道,对IL-2和IL-15之间的功能差异提供了关键的机理和结构见解,这些功能差异高度相关,并将IL-2RBETA和GC作为受体成分共享,但仍然具有独特的生物学功能。尽管IL-2主要通过顺式信号和IL-15信号通过反式信号,但这些细胞因子基本上具有STAT,PI3K/AKT和RAS/MAPK信号通路的STAT基本相同激活。此外,基因表达谱非常相似,尽管并不相同。因此,尽管生物学反应不同,这些细胞因子几乎具有几乎无法区分的信号传导特性。这项研究已实质上阐明了IL-2和IL-15信号的结构和机械方面。
以前,我们证明IL-21通过依赖于STAT3和IRF4的响应元件编码BLIMP1的PRDM1基因的表达。这导致我们在过去一年中的报道是,与已知与B细胞中PU.1合作通过ETS-IRF复合元件(EICES)作用的能力相反,IRF4与BATF/JUN家族蛋白合作通过T细胞中的AP1-IRF复合元素(AICE)和B细胞以及B细胞以及B细胞以及BATF/JUN家族蛋白合作。我们证明了通过这些AICS对重要基因进行关键的合作调节,并证明了IRF4,BATF和JUN家族蛋白的合作结合,并且在BATF缺陷型细胞中的IRF4结合显着降低,并且在IRF4缺乏细胞中显着减少了BATF的结合。我们证明了关键基因的批判性调节,包括例如那些通过AICE编码IL-10和IL-17的人。在与肯·墨菲(Ken Murphy)的合作研究中,我们还报告说,BATF因子在涉及BATF的Leucine Zipper域的BATF-IRF相互作用介导的树突状细胞发育中存在重要的补偿作用。
我们还报道了IL-21/STAT3和GM-CSF/STAT5之间的串扰的关键作用。 IL-21对T型和B细胞有广泛的行动,但其先天免疫的行为知之甚少。我们报道了IL-21通过STAT3和BIM诱导常规树突状细胞(CDC)的凋亡,这受到粒细胞巨噬细胞刺激因子(GM-CSF)的抑制。 CHIP-SEQ分析显示,GM-CSF诱导的STAT5和IL-21诱导的STAT3之间的全基因组结合竞争。 IL-21在体内的表达降低了CDC的数量,这是GM-CSF预防的。此外,小鼠的重复α-半乳糖基酰胺注射会诱导IL-21,但自然杀伤剂T(NKT)细胞降低了GM-CSF的产生,与CDC数量降低相关。此外,野生型CD4+ T细胞的产物转移导致DCS和干扰素增加(IFN)-γ产生CD4+ T细胞在IL21R - / - rag2-/ - 小鼠中(缺乏T缺乏T细胞并且具有IL-21-无响应DCS)而不是RAG2 - / - / - / - / - / - / - / - / - / - 鼠标。因此,IL-21和GM-CSF对基因调节和凋亡,调节CDC数量以及免疫反应的幅度表现出交叉调节作用。
总体而言,以上发现增强了我们对GC家族细胞因子调节基因表达和生物学重要过程的机制的理解。此外,这些发现具有与癌症,自身免疫性和其他疾病的治疗有关的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Warren J Leonard其他文献
Warren J Leonard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Warren J Leonard', 18)}}的其他基金
IL-2 Family Cytokines and their Receptors-- Biology of the IL-21 system
IL-2 家族细胞因子及其受体——IL-21 系统的生物学
- 批准号:
8939804 - 财政年份:
- 资助金额:
$ 130.4万 - 项目类别:
IL-2 Family Cytokines and their Receptors-- Biology of the IL-21 system
IL-2 家族细胞因子及其受体——IL-21 系统的生物学
- 批准号:
8344812 - 财政年份:
- 资助金额:
$ 130.4万 - 项目类别:
IL-2 Family Cytokines and their Receptors-- Molecular Regulation via GABP
IL-2 家族细胞因子及其受体——通过 GABP 进行分子调控
- 批准号:
7735035 - 财政年份:
- 资助金额:
$ 130.4万 - 项目类别:
IL-2 Family Cytokines and their Receptors-- Biology of the IL-2 system
IL-2 家族细胞因子及其受体——IL-2 系统的生物学
- 批准号:
10262667 - 财政年份:
- 资助金额:
$ 130.4万 - 项目类别:
IL-2 Family Cytokines and Receptors-- Mechanisms of Regulation & Action
IL-2 家族细胞因子和受体——调节机制
- 批准号:
10262668 - 财政年份:
- 资助金额:
$ 130.4万 - 项目类别:
相似海外基金
Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma
调节PD-1/PD-L1检查点促进肉瘤患者HER2 CAR T细胞的抗肿瘤活性
- 批准号:
10562836 - 财政年份:2023
- 资助金额:
$ 130.4万 - 项目类别:
“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”
– NR4A1 和 NR4A2 的药理学靶向激活胶质母细胞瘤治疗反应 –
- 批准号:
10744524 - 财政年份:2023
- 资助金额:
$ 130.4万 - 项目类别:
Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation
将来自免疫活性干细胞供体的疫苗诱导的免疫力转移作为抗病毒免疫疗法,以保护高危移植受者免受巨细胞病毒再激活
- 批准号:
10659635 - 财政年份:2023
- 资助金额:
$ 130.4万 - 项目类别:
Optimizing CAR T therapy via metabolic engineering for thetreatment of GBM
通过代谢工程优化 CAR T 疗法治疗 GBM
- 批准号:
10722922 - 财政年份:2023
- 资助金额:
$ 130.4万 - 项目类别:
Next generation T cell therapies for mutant KRAS solid tumors
针对突变 KRAS 实体瘤的下一代 T 细胞疗法
- 批准号:
10731929 - 财政年份:2023
- 资助金额:
$ 130.4万 - 项目类别: